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Matriptase Induction of Metalloproteinase-Dependent
Aggrecanolysis In Vitro and In Vivo
Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms
David J. Wilkinson,1 Angela Habgood,1 Heather K. Lamb,1 Paul Thompson,1
Alastair R. Hawkins,1 Antoine Desilets,2 Richard Leduc,2 Torsten Steinmetzer,3
Maya Hammami,3 Melody S. Lee,4 Charles S. Craik,4 Sharon Watson,1 Hua Lin,1
Jennifer M. Milner,1 and Andrew D. Rowan1
Objective. To assess the ability of matriptase, a
type II transmembrane serine proteinase, to promote
aggrecan loss from the cartilage of patients with osteoar-
thritis (OA) and to determine whether its inhibition can
prevent aggrecan loss and cartilage damage in experimen-
tal OA.
Methods. Aggrecan release from human OA carti-
lage explants and human stem cell–derived cartilage discs
was evaluated, and cartilage-conditioned media were used
for Western blotting. Gene expression was analyzed by
real-time polymerase chain reaction. Murine OA was
induced by surgical destabilization of the medial menis-
cus, and matriptase inhibitors were administered via
osmotic minipump or intraarticular injection. Cartilage
damage was scored histologically and aggrecan cleavage
was visualized immunohistochemically using specific
neoepitope antibodies.
Results. The addition of soluble recombinant
matriptase promoted a time-dependent release of aggre-
can (and collagen) from OA cartilage, which was sensitive
to metalloproteinase inhibition and protease-activated
receptor 2 antagonism. Although engineered human (nor-
mal) cartilage discs failed to release aggrecan following
matriptase addition, both matrix metalloproteinase– and
aggrecanase-mediated cleavages of aggrecan were detected
in human OA cartilage. Additionally, while matriptase did
not directly degrade aggrecan, it promoted the accumula-
tion of low-density lipoprotein receptor–related protein 1
(LRP-1) in conditioned media of the OA cartilage
explants. Matriptase inhibition via neutralizing antibody
or small molecule inhibitor significantly reduced cartilage
damage scores in murine OA, which was associated with
reduced generation of metalloproteinase-mediated aggre-
can cleavage.
Conclusion. Matriptase potently induces the
release of metalloproteinase-generated aggrecan fragments
as well as soluble LRP-1 from OA cartilage. Therapeutic
targeting of matriptase proteolytic activity reduces metallo-
proteinase activity, further suggesting that this serine pro-
teinase may have potential as a disease-modifying therapy
inOA.
Osteoarthritis (OA) is the most common form of
arthritis and a major cause of pain and disability in older
adults. Although often considered a degenerative joint dis-
ease mediated by wear and tear and an inevitable
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consequence of aging, OA results from abnormal remodel-
ing of joint tissues. Common risk factors include age, sex,
prior joint injury, obesity, and mechanical factors. More-
over, there is now greater appreciation of the role of inflam-
mation in human OA, and animal studies suggest that
multiple, distinct biologic pathways contribute to disease
initiation and progression in different OA models. Various
mediators include double-stranded RNA, Toll-like recep-
tors (1,2), Wnt, transforming growth factor b, CXC
chemokines, Indian hedgehog, alarmins, and intracellular
zinc (3,4). Such observations have led to the paradigm that
during OA progression, chondrocytes undergo a pheno-
typic shift which detrimentally disturbs cartilage
homeostasis.
Our findings in previous studies have implicated ser-
ine proteinases in the proteolytic cascades that lead to carti-
lage destruction (5–8), and proteinase localized at the cell
surface would be ideally placed to initiate the observed peri-
cellular degradation of articular cartilage (9). In particular,
we have reported a novel mechanism in OA whereby the
type II transmembrane serine proteinase matriptase can
drive cartilage collagenolysis by directly inducing and acti-
vating the pro forms of matrix metalloproteinases (MMPs)
as well as by activating the G protein–coupled receptor,
protease-activated receptor 2 (PAR-2) (10). PAR-2, which
can also be activated by several other serine proteinases, is
expressed in numerous tissues (11) and has been demon-
strated to be a pivotal player in mediating chronic joint
inflammation (12). PAR-2 deficiency is chondroprotective
in the destabilization of the medial meniscus (DMM)
murinemodel ofOA (13), in which abnormal biomechanics
trigger and potentiate OA (14). Recent findings confirm
the high mechanosensitivity proteinase genes which are
rapidly expressed following induction of experimental OA
(15), and our own previous data confirmed elevated expres-
sion of bothmatriptase and PAR-2 followingDMM(10).
Taken together, these findings suggest that target-
ing PAR-2 activators (which vary between tissues), rather
than PAR-2 directly, will help provide specificity and could
therefore have potential as a disease-modifying OA drug
(DMOAD). Indeed, the proteolytic loss of type II collagen
from cartilage is essentially irreversible (16), making such
contributors to this process key therapeutic targets. Despite
the well-characterized involvement of metalloproteinases,
including MMPs, inhibitors targeting this family of
proteinases have not proven efficacious in arthritis (17).
The loss of the highly sulfated proteoglycan, aggrecan,
from cartilage is considered to be an essential prerequisite
for collagenolysis to ensue during disease (18,19); ADAMTS
enzymes, such as the mechanosensitive aggrecanase
ADAMTS-5 (15), are widely implicated. Thus, blockade of
aggrecanolysis could provide long-term benefit to the integ-
rity of the cartilage extracellularmatrix.
The aim of the present study was to investigate the
ability of matriptase to affect aggrecan release from human
cartilage. We also sought to determine whether matriptase
inhibition could reduce aggrecanolysis, and thus diminish
the severity of cartilage damage, in murine OA.
MATERIALS AND METHODS
Reagents. All chemicals and reagents were of the highest
purity available. Interleukin-1a (IL-1a) was a generous gift from
Dr. Keith Ray (GlaxoSmithKline, Stevenage, UK). Oncostatin M
(OSM)was produced in-house as previously described (20), or pur-
chased from R&D Systems. GM6001, a broad-spectrum MMP
inhibitor, was purchased from Calbiochem. ENMD-1068 was from
Enzo Life Sciences. ADAMTS-5 was a kind gift from Professor
Hideaki Nagase (Oxford, UK). MMP-13 was produced as previ-
ously described (21). Bovine trypsin was from Sigma-Aldrich. Puri-
fied full-length human placental low-density lipoprotein receptor–
related protein 1 (LRP-1) was from BioMac. Anti–LRP-1 anti-
bodies 8G1 (ab20384) and 5A6 (ab28320) were from Abcam, and
neoepitope N-terminal aggrecan fragment antibodies BC-3 and
BC-14 were generously provided by Professor Bruce Caterson
(Cardiff, UK). Antibodies to neoepitope C-terminal aggrecan
fragments (VDIPEN and NVTEGE), MMP-13–cleaved collagen
II neoepitope (GPHyGPQG), and the aggrecan G1 domain were
kind gifts from Dr. John Mort (Montreal, Quebec, Canada). Anti-
matriptase antibody A11 was produced as previously described
(22), and deglycosylated aggrecan was prepared as described (23).
Boc-Gln-Ala-Arg-NHMec (Boc-QAR-NHMec)was fromBachem
and Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (FS-6) was
from Sigma-Aldrich. The matriptase inhibitor (S)-3-amino-N-(3-
(N-(1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3-carbamimidoylphenyl)-
1-oxopropan-2-yl)sulfamoyl)phenyl)propanamide3 3HCl (referred
to as compound 59 in ref. 24) was produced in-house (24,25) or bulk
synthesized by Sygnature.
Recombinant matriptase expression. Recombinant
matriptase (catalytic domain; amino acids 596–855) was prepared
at 48C essentially as described previously (26). Following expres-
sion, pelleted bacterial cells (50 gm) were sonicated for 20
minutes (15 mm amplitude) in 2 3 450 ml of 0.1M Tris, 0.3M
NaCl (pH 8.0) (buffer 1) while cooling in an ice/water mix, and
then centrifuged at 10,000g for 40 minutes. Pellets were washed
with buffer 1 before combining with 450 ml of 50 mM Tris, 6.0M
urea, 1 mM b-mercaptoethanol (pH 8.0) (buffer 2), sonicated,
stirred for 15 minutes, and centrifuged at 10,000g for 60 minutes.
The supernatant was applied to a ProBond column (50 ml; Life
Technologies), equilibrated with buffer 2, and purified with His-
tagged protein, according to the instructions of themanufacturer.
Matriptase-containing fractions, identified by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE; Life
Technologies), were pooled and dialyzed (each 5 liters) (once in
50 mM Tris, 3.0M urea, 10% weight/volume [w/v] glycerol, 1 mM
b-mercaptoethanol [pH 9.0] and twice in 50 mM Tris, 1 mM b-
mercaptoethanol [pH 9.0] [buffer 3]). After dialysis, matriptase
was purified on a MONO Q 10/100 GL column with an elution
gradient of 0.0–1.0M NaCl in buffer 3. Fractions containing
matriptase, identified by SDS-PAGE (.95% purity), were
pooled and stored at2808C.
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Enzyme assays and inhibitor characterization.
Active-site titration of serine proteinases was performed using 4-
methylumbelliferyl 4-guanidinobenzoate HCl. Serine proteinase
activity assays were performed in 0.1M Tris HCl, 0.15MNaCl (pH
9.0), 500 mg/ml bovine serum albumin, 0.01% (w/v) Brij-35, while
MMP activity assays used 0.1M Tris, 0.15M NaCl, 10 mM CaCl2,
0.05% (w/v) Brij-35, 0.1% (w/v) polyethylene glycol 6000 (pH 7.5).
Serine proteinase and MMP activities were monitored by mea-
surement of the increase in fluorescence from 50 mM Boc-QAR-
NHMec (excitation 360 nm; emission 460 nm) or 50 mM FS-6
(excitation 320 nm; emission 405 nm), respectively, at 378C in an
LS50B fluorometer (PerkinElmer); 4-APMA was included in
MMP assays to assess total MMP activity as previously described
(27). The inhibitory property of compound 59 was verified by
determination of the 50% inhibition concentration against
matriptase, calculated from the percentage inhibition across a
range of inhibitor concentrations. Dose-response curves were gen-
erated using GraphPad Prism 5.0 software. Ki values were then
determined using the Cheng-Prusoff equation (28).
Animals. Experiments were performed on 10-week-old
male wild-type C57BL/6J mice (weighing 25–30 gm). Mice were
housed in standard cages with food and water available ad libitum
(maintained in a thermoneutral environment). All procedures
were performed in accordance with current UK Home Office
regulations. OA in C57BL/6J mice was induced surgically by
DMM; in a previous study, this resulted in medial and posterior
rotation of themedialmeniscus, leading to amild formofOA (15).
Sham operations were performed in some animals. Anti-
body A11 was delivered via intraperitoneal osmotic pump (Alzet
1004) of 100 ml capacity, delivering 1.5 mg of antibody/day at a
rate of 0.11 ml/hour for 4 weeks. Compound 59 was delivered at
5, 25, or 50 mg/kg/day via a subcutaneously implanted osmotic
pump (Alzet 2004) of 200 ml capacity with a delivery rate of 0.25
ml/hour for 4 weeks. Both reagents were formulated in 0.9%
saline, which was also used as vehicle-only control. After 4 weeks,
fresh osmotic pumps were inserted, with identical contents. Com-
pound 59 was also administered to separate animals via 5 ml
intraarticular injection of a 10 mg/ml solution (or saline alone as
a control) at the time of surgery and again 1 week postsurgery.
Mice treated with intraarticular injections or minipumps were
killed 4 weeks or 8 weeks, respectively, after surgery, and knee
joints harvested for histologic examination. Cartilage damage and
osteophytes were graded under blinded conditions by 2 indepen-
dent observers. according to previously described grading systems
(29,30).
Immunohistochemistry. Decalcifiedmurine knee joints
were embedded in paraffin wax. Sections of joint tissue (6 mm)
were deparaffinized and rehydrated, and antigen retrieval was
performed using 1% (w/v) hyaluronidase (from bovine testes)
incubated at 378C for 30 minutes. Sections were then blocked
with horse serum for 20 minutes and incubated with one of the
following antibodies for 30 minutes at room temperature: anti-
VDIPEN (MMP-cleaved aggrecan; 1:500 dilution), anti-NVTEGE
(ADAMTS-cleaved aggrecan; 1:400 dilution), or anti-GPHyGPQG
(collagenase-cleaved type-II collagen; 1:400 dilution). After wash-
ing, sections were incubated with ImmPress Reagent (Vector)
for 30 minutes. Signal was developed using 3,30-diaminobenzidine
tetrahydrochloride (Dako) with hematoxylin counterstaining,
according to the protocol recommended by the manufacturer
(Dako). Images were captured using a 3-CCD color video camera
(JVC).
Human cartilage. Macroscopically normal articular car-
tilage was obtained from patients withOA (age range 59–85 years;
92% female) who had undergone total knee replacement surgery
in hospitals in Newcastle upon Tyne. The patients provided
informed consent and the study was performed with ethics com-
mittee approval. Cartilage was dissected into ;2 3 2 3 2–mm
pieces, plated into 24-well tissue culture plates (3 pieces/well,
n5 4) in serum-free medium, and incubated for 14 days in the
presence of soluble recombinant matriptase (with or without
inhibitors), with medium changed after 7 days, as previously
described (10). For comparison purposes, some cartilage speci-
mens were cultured with the potent catabolic stimulus of IL-1 plus
OSM, as previously reported (10).
Viability of cartilage explants was assessed by screening
for adenylate kinase (AK) production using the ToxiLight Bioas-
say Kit (Lonza) (10). No increases in AK levels with any of the
matriptase treatments were observed. Serum was excluded from
explants since it can contain anabolic factors that can markedly
alter the metabolism of cartilage; such exclusion does not affect
tissue viability or responsiveness (31).
Cartilage discs derived from human mesenchymal stem
cells (MSCs; Lonza) were generated as described (32) and used
as amodel of normal human cartilage. In all cartilage experiments,
we used 100 nM matriptase, a concentration that was determined
empirically to be optimal for the induction of human OA cartilage
collagen and glycosaminoglycan (GAG) release (see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.40133/abstract).
Total RNA from cultured knee cartilage samples was prepared
as described (7), or cartilage remaining at the final day of cul-
ture was digested with papain (31), and all samples were stored
at 2208C until assayed. Measurements of hydroxyproline (33)
and sulfated GAG (34) were used as estimates of cartilage col-
lagen and aggrecan, respectively. Cumulative release was calcu-
lated and expressed as a percentage of the total for each well,
as described previously (31).
In vitro assays, SDS-PAGE, and immunoblotting.
Recombinant human matriptase (or bovine trypsin) was incu-
bated with either aggrecan (1:40 enzyme:substrate ratio) or with
purified LRP-1 (1:5 enzyme:substrate ratio) in 0.1M Tris HCl
(pH 8.5), 0.15M NaCl, 0.01% (w/v) Brij-35 at 378C. Products
were separated by SDS-PAGE and gels were stained with silver
or semidry blotted onto PVDF. Aggrecan digests were probed
with an antibody recognizing the G1 domain of aggrecan, while
LRP-1 immunoblotting was performed under nonreducing con-
ditions in accordance with the instructions of the manufacturer.
Reactivity was detected with enhanced chemiluminescence sub-
strate and visualized using Genesnap photo capture software
(Syngene). Since loading controls for cartilage conditioned media
are not possible due to the absence of control proteins in serum-
free medium, equal volumes of conditioned media from human
OA cartilage explants were resolved by SDS-PAGE and subse-
quently immunoblotted.
Real-time polymerase chain reaction (PCR) of rela-
tive messenger RNA levels. For TaqMan PCR, relative gene
expression was calculated using the DDCt method and corrected
according to 18S ribosomal RNA levels. Cycling conditions
(7900HT system; Applied Biosystems) for TaqMan PCR
(TaqMan gene expression Master Mix; Applied Biosystems)
were as follows: 10 minutes at 958C, then 40 cycles of 15 seconds
at 958C, and 1 minute at 608C. Human primer/probe sequences
for TaqMan PCR have been previously described (35).
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Statistical analysis. Cartilage experiments were per-
formed at least in quadruplicate for 3 different cartilage samples,
and as.2 conditions were compared simultaneously, significance
was assessed using analysis of variance with Bonferroni post hoc
test for multiple comparisons, using GraphPad Prism 5.0 soft-
ware. Standard TaqMan experiments were performed at least in
triplicate on aminimum of 2 separate samples, with data analyzed
using Student’s 2-tailed t-test. Significant differences between car-
tilage damage scores of knee joints (typically n5 10 per treat-
ment group) were assessed by Mann-Whitney 2-tailed U test, or,
for experiments comparing .1 dose, a Kruskal-Wallis nonpara-
metric test with Dunn’s multiple comparison test. For clarity,
only selected comparisons are presented in some figures, where P
values were,0.001,,0.01, or,0.05.
RESULTS
Aggrecan release from OA cartilage promoted
by matriptase. Addition of recombinant matriptase to
humanOA cartilage in ex vivo culture over a 14-day period
resulted in a time-dependent release of collagen, as previ-
ously reported (10), unlike the findings obtained with the
potent pro-catabolic stimulus IL-1 plus OSM (Figure 1A).
This effect was markedly blocked by inclusion of the
metalloproteinase inhibitor GM6001 (Figure 1B). Release
of aggrecan following matriptase stimulation was as pro-
nounced as that observed with IL-1 plus OSM stimulation
(Figure 1A), and was again reduced to control levels in the
presence of GM6001 (Figure 1B). Cartilage remained via-
ble on day 14 in serum-free medium as shown previously
(5), and only IL-1 plus OSM exhibited slight toxicity
(,10%) (see Supplementary Figure 2, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40133/abstract) (36). Further-
more, inclusion of the PAR-2 antagonist ENMD-1068
reduced aggrecan release (data not shown), as described
previously (10). Finally, assessment of the expression of
the ADAMTS aggrecanases ADAMTS4 and ADAMTS5
revealed a rapid, significant induction of ADAMTS4 on
day 1 following addition of matriptase to human OA carti-
lage. Although not significant, this trend continued to day
7 (Figure 1C); no alterations in ADAMTS5 expression
were observed.
Time-course data from studies of conditioned
media from OA cartilage revealed that matriptase
appeared to promote both MMP- and ADAMTS-
Figure 1. Promotion of aggrecan and collagen release from osteoarthritis (OA) cartilage by matriptase. Human OA cartilage explants were incu-
bated with control medium or with interleukin-1 (IL-1) plus oncostatin M (OSM) (1 ng/ml and 10 ng/ml, respectively) or matriptase (100 nM)
with or without GM6001 (10 mM). Cultures were stimulated for 1, 7, or 14 days (A), 14 days (B), or 3 days (C). A and B, Collagen release
(expressed as a percentage of the total collagen present) was determined by hydroxyproline measurement (top panels), and aggrecan release
(expressed as a percentage of the total) was measured as glycosaminoglycan (GAG) release (bottom panels). Values are the mean6 SD (n5 4).
***5P, 0.001 versus control medium; †††5P, 0.001 versus matriptase only; ###5P, 0.001 versus IL-1 plus OSM only, by analysis of vari-
ance with Bonferroni post hoc test. C, For measurement of matriptase-induced expression of ADAMTS proteinases, total RNA was isolated,
reverse transcribed, and subjected to real-time polymerase chain reaction. Results are relative expression levels normalized to the 18S ribosomal
RNA housekeeping gene. Values are the mean6 SEM. *5P, 0.05 versus control, by Student’s 2-tailed t-test. All data in A–C are representa-
tive of 2–4 independent experiments.
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mediated cleavage of aggrecan within the interglobular
domain, as evidenced by specific neoepitope antibodies
(Figure 2A). Consistent with the lack of collagen release
from human OA cartilage, IL-1 plus OSM promoted only
ADAMTS-mediated cleavage and not that generated by
active MMPs. Specificity of the neoepitope antibodies was
confirmed using recombinant MMP-13 and ADAMTS-5
with deglycosylated aggrecan (data not shown). We also
found that matriptase, unlike trypsin, failed to degrade the
aggrecan monomer in vitro as evidenced by silver staining
and anti-G1 antibody staining (Figure 2B), suggesting little
capacity to directly cleave the aggrecan core protein. To
assess the ability of matriptase to promote aggrecan
release from normal human cartilage, we used a stem cell–
derived model (Figure 2C). We found that matriptase
alone failed to significantly induce either collagen release
(as previously reported) (10) or aggrecan release (Figure
2D). Conversely, IL-1 plus OSM alone was able to pro-
mote significant aggrecan release, and in combination with
matriptase also promoted the release of collagen, which
was associated with the presence of active MMPs in the
conditioned medium (Figure 2D).
Release of LRP-1 by matriptase. Since LRP-1,
an endocytic receptor for ADAMTS-5, ADAMTS-4, and
MMP-13 (37–39), has been shown to be a key regulator of
the proteolytic burden in cartilage, we hypothesized that
matriptase could promote its release—a process likely to
be important during cartilage destruction in OA (37).
While low levels of high molecular weight LRP-1 were
detected in control cultures, as has also been observed by
others previously (Yamamoto K: personal communica-
tion), addition of matriptase to human OA cartilage led to
the detection of soluble fragments of the N-terminal a sub-
unit of LRP-1 in day 7–conditioned medium (Figure 3A).
Figure 2. Promotion of matrix metalloproteinase (MMP)– and aggrecanase-mediated aggrecan breakdown from OA cartilage by matriptase.
Human OA cartilage explants were incubated with control medium with or without matriptase (100 nM) or IL-1 plus OSM (1 ng/ml and 10 ng/
ml, respectively). A, Western blotting of conditioned media (10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis [SDS-PAGE]) with
the MMP-specific neoepitope antibody BC-14 (top) or the ADAMTS-specific neoepitope antibody BC-3 (bottom) was performed for the indi-
cated numbers of days. The results demonstrate cumulative increases in both neoepiptopes over time with matriptase treatment, and in the
ADAMTS-specific epitope with IL-1 plus OSM treatment. B, Deglycosylated aggrecan was incubated with matriptase or trypsin, and the
resulting cleavage products were resolved by 7.5% SDS-PAGE and visualized by silver staining (top) or Western blotting with an anti-G1 anti-
body (bottom). C, Cartilage discs derived from human mesenchymal stem cells were assessed for proteoglycan content by staining with Safranin
O (top) or Alcian blue (middle), and for collagen content by staining with Masson’s trichrome (bottom). Original magnification3 5. D, After the
discs were cultured in the presence of IL-1 plus OSM and/or matriptase for 14 days, cumulative collagen release and aggrecan (GAG) release
was measured (top). MMP activity (either active or total [pretreated with APMA]) in day 14 conditioned media was determined using the
fluorogenic substrate FS-6 (bottom). Values are the mean6 SD (n5 5 or more samples per group). ***5P , 0.001; **5P, 0.01 versus control
with no stimulation, by analysis of variance with Bonferroni post hoc test. All results are representative of 2–4 separate experiments. See Figure 1 for
other definitions. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40133/abstract.
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Figure 3. Matriptase cleavage of low-density lipoprotein receptor–related protein 1 (LRP-1). A, Conditioned media from unstimulated (control)
and matriptase-stimulated human osteoarthritis cartilage were harvested for the indicated number of days. Equal volumes of media (24 ml) were
separated by 6% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting with an anti–LRP-1 antibody
recognizing the N-terminal domain. B, Matriptase was incubated with purified LRP-1 in vitro at a 1:5 enzyme:substrate ratio for the indicated
number of hours. Digested products were separated by either 6% or 4–15% SDS-PAGE and Western blotting with anti–LRP-1 antibodies recog-
nizing the N-terminal (top) and C-terminal (bottom) domains, respectively. Results are representative of 3 independent experiments.
Figure 4. Matriptase-neutralizing antibody protects against in vivo aggrecan loss in an osteoarthritis (OA) model. OA was induced in C57BL/6J
mice following destabilization of the medial meniscus (DMM) surgery. Simultaneously, antibodies in 0.9% saline (either the A11 neutralizing
matriptase antibody [n5 12] or an isotype control [n5 6]), at 1.5 mg/day were administered via intraperitoneal osmotic minipump. Pumps were
replaced at 4 weeks, and animals were killed at 8 weeks postsurgery. A, Consecutive knee joint sections (6 mm) were stained with hematoxylin–
Safranin O–fast green. Sections from 2 representative DMM-treated animals and 1 representative sham-treated animal in each antibody-treated
group are shown. Original magnification3 10. B, Approximately 10 sections from each mouse were graded by 2 independent observers who were
blinded with regard to treatment group, using the following scoring systems: for cartilage damage, 0 (normal) to 6 (vertical clefts/erosion to the
calcified cartilage extending to .75% of the articular surface) (29); for osteophyte size relative to the adjacent cartilage, 0 (none), 1 (small: simi-
lar thickness), 2 (medium: 1–3-fold increased thickness), or 3 (large: .3-fold increased thickness) (30). Bars show the mean6SD of the highest
scores in the medial tibial and femoral condyles for each joint. **5P, 0.01, by Mann-Whitney U test. NS5not significant. Color figure can be
viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40133/abstract.
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This was not reduced following inclusion of the metallo-
proteinase inhibitor GM6001, and no LRP-1 C-terminal b
subunit fragments were detected in these experiments
(results not shown). To confirm cleavage by matriptase,
purified LRP-1 incubated with matriptase-generated
degradation fragments of the 515 kd a subunit of LRP-1
(but not the 85 kd b subunit of LRP-1) were detected, con-
sistent with ex vivo findings (Figure 3B).
Reduction of in vivo aggrecanolysis by inhibi-
tion of matriptase activity in experimental OA. The
neutralizing antibody A11 has been shown to be an effective
matriptase inhibitor (22), and treatment of mice with A11
following OA induction by DMM reduced cartilage damage
as evidenced by Safranin O staining (Figure 4A) and as
shown by decreased cartilage damage scores (Figure 4B),
while osteophyte grading showed no reduction in the size of
osteophytes with A11 antibody treatment (Figure 4B). Ki
determination data confirmed a very similar inhibitory pro-
file for the small molecule matriptase inhibitor, compound
59 (Ki5 3.7 nM), as reported previously (24), while isother-
mal titration calorimetry measurements confirmed a 1:1
stoichiometry with high affinity (Kd5 20 nM) between
compound 59 and matriptase (see Supplementary Figure 3
and Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.40133/abstract). Compound 59 reduced aggre-
can loss and cartilage damage scores even at the lowest dose
used (Figures 5A and B). While there was a trend toward
reduced osteophyte size with increasing dose of compound
59, this did not reach statistical significance (P5 0.0525 at
50 mg/kg/day) (Figure 5B). Furthermore, 2 intraarticular
injections of compound 59 on days 0 and 7 post–DMM sur-
gery were sufficient to confer significant protection against
cartilage damage (Figures 5C and D), but no difference in
osteophyte size was observed (Figure 5D). No cartilage
damage was observed following intraarticular injection of
saline in sham-treated joints.
We also observed no differences in osteophyte matu-
rity between vehicle- and matriptase inhibitor–treated joints
(results not shown). As previously reported (14), we found
cartilage damage to the tibial plateau to be most marked fol-
lowing DMM (Figures 6A and B). Immunohistochemical
assessment of DMM-treated joint sections with 3 neoepitope
antibodies recognizing ADAMTS-cleaved (anti-NVTEGE)
Figure 5. Matriptase inhibition protects against in vivo aggrecan loss in an osteoarthritis (OA) model. OA was induced in C57BL/6J mice following
destabilization of the medial meniscus (DMM) surgery, while some animals underwent only sham surgery. Simultaneously, 0.9% saline alone (con-
trol; n5 15) or compound 59 in 0.9% saline at 5 mg/kg/day (n5 15), 25 mg/kg/day (n5 14), or 50 mg/kg/day (n5 13) was administered via subcuta-
neous osmotic minipump. Pumps were replaced at 4 weeks, and animals were killed at 8 weeks postsurgery (A and B). Alternatively, mice received
5-ml intraarticular injections (10 mg/ml; n5 12 in both groups) on days 0 and 7 postsurgery (C and D). Consecutive knee joint sections (6 mm)
were stained with hematoxylin–Safranin O–fast green. Images from a representative animal in each treatment group are shown. Original
magnification3 10 (A and C). Sections from each mouse were graded (as described in Figure 4) by 2 independent observers who were blinded with
regard to treatment group. Bars show the mean6 SD of the highest scores in the medial tibial and femoral condyles for each joint. **5P, 0.01;
***5P , 0.001, by Kruskal-Wallis test with Dunn’s multiple comparison test (B) or by Mann-Whitney U test (D). NS5 not significant. Color fig-
ure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40133/abstract.
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and MMP-cleaved (anti-VDIPEN) aggrecan, as well as
collagenase-cleaved type II collagen (anti-GPHyGPQG),
confirmed that matriptase inhibition reduced antibody
staining at or adjacent to sites of damage compared to
that in saline-treated control joints (Figures 6C and D).
DISCUSSION
The discovery that distinct biologic pathways (for
review, see refs. 3 and 4) are involved in OA initiation and
progression represents major breakthroughs in the quest
for effective therapies for this debilitating disease.
Although there are currently no effective DMOADs, we
are now beginning to better understand OA pathogenesis
and, importantly, where such interventions could be effec-
tive. Our discovery of matriptase as a novel initiator of
human cartilage degradation in OA represents one such
pathway with therapeutic potential (10). In the present
study, our findings demonstrated that matriptase is a
potent inducer of aggrecan and collagen release from OA
cartilage and that this is dependent upon metalloprotein-
ase activity. The rapid release of aggrecan was associated
with the generation of both MMP- and ADAMTS-
mediated cleavages of aggrecan unlike the potent cytokine
stimulus of IL-1 plus OSMwhich only affected ADAMTS-
mediated cleavages.
Moreover, multiple immunoreactive aggrecan
fragments further highlight the potent consequences of
matriptase action via numerous metalloproteinases. We
hypothesize that although stimulation of human cartilage
with IL-1 plus OSM typically induces the expression and
production of proMMPs (27), activation of such pre-
cursors to levels sufficient to drive collagenolysis does not
occur in culture, as demonstrated by the absence of detect-
able collagen fragments from human OA- or MSC-derived
cartilage. Exogenous addition of the proMMP activator
plasminogen is, however, sufficient to drive collagen
release in, for example, IL-1 plus OSM–stimulated human
Figure 6. Matriptase inhibition blocks in vivo metalloproteinase activity in an osteoarthritis (OA) model. OA was induced in C57BL/6J mice fol-
lowing destabilization of the medial meniscus surgery. Simultaneously, 0.9% saline alone (A and C) or compound 59 in 0.9% saline at 50 mg/kg/
day (B and D) was administered via subcutaneous osmotic minipump. Pumps were replaced at 4 weeks, and animals were killed at 8 weeks
postsurgery. Consecutive knee joint sections (6 mm) were stained with hematoxylin–Safranin O–fast green. Sections were stained with neoepitope
antibodies (C and D), showing matrix metalloproteinase–cleaved aggrecan sequence VDIPEN (i), ADAMTS-cleaved aggrecan sequence
NVTEGE (ii), or collagenase-cleaved type II collagen sequence GPHyPGPQG (iii), or with no primary antibody (control) (iv). Images from a
representative animal in each treatment group (n5 3 per group) are shown. Bars5 50 mm. In A and B, areas denoted by dashed lines in the
upper panels are shown at higher magnification in the lower panels (original magnification 3 20 and 3 40, respectively).
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OA cartilage explants (5), and we have previously demon-
strated the ability of matriptase to activate proMMPs and
enhance cytokine-stimulated cartilage breakdown (10),
consistent with the data from the present study.
Interestingly, although matriptase is a trypsin-like
serine proteinase, it did not significantly degrade the
aggrecan monomer in vitro, unlike trypsin itself. This sug-
gests that the substrate specificity of matriptase is more
restricted than that of trypsin, which is supported by previ-
ous studies (40,41), such that the observed aggrecanolysis
is essentially indirect by other proteinases. This was further
supported by the finding that ADAMTS4 (but not
ADAMTS5) as well as MMPs (10) were induced following
matriptase addition to OA cartilage.
The cell surface scavenger receptor LRP-1
mediates cellular reuptake of several molecules that are
important for maintaining cartilage homeostasis, including
metalloproteinases such as ADAMTS-5, MMP-13, and
ADAMTS-4 (37–39). It has been hypothesized that LRP-1
“shedding” from the chondrocyte surface may play a key
role in the accumulation of destructive proteinases during
OA cartilage degradation in the absence of increased pro-
teinase expression.
In the present study, we demonstrated for the first
time that matriptase has the capacity to cleave LRP-1 in
both ex vivo and in vitro systems. The most common
region for LRP-1 ligand binding is cluster II, close to the
N-terminus (Yamamoto K: personal communication).
Given that the 515-kd fragment of LRP-1 along with
matriptase-generated fragments of 200 kd and 100 kd
were detected in vitro by Western blotting with an anti-
body specific for the N-terminus, we conclude that if such
cleavage occurs in vivo, cluster II would be released.
Although these findings provide interesting insight into the
potential “shedding” of LRP-1 by matriptase, further stud-
ies are required to identify specific cleavage sites and con-
firm pathologic significance. Membrane-bound MMP-14
has been shown to shed LRP-1 (42), and our data clearly
suggests that matriptase may also play a further indirect
role in cartilage degradation via cleavage of LRP-1,
resulting in an accumulation of metalloproteinases and
thus elevating the proteolytic burden within the extracellu-
lar matrix.
Our previous study demonstrated that PAR-2 and
matriptase are coexpressed in murine OA cartilage (10).
The absence of cartilage damage in DMM-treated PAR-2–
deficient mice further highlights the importance of PAR-2
in murine OA (13), as well as in inflammatory arthritis
(12,43,44). Moreover, we have previously reported that nor-
mal human cartilage fails to resorb following addition of
exogenous matriptase, which was further supported in the
present study by our use of MSC-derived human cartilage.
We hypothesize that this was due to PAR-2 levels being
below a critical threshold level, as indeed are (latent) MMP
levels (10). Therapeutic targeting of PAR-2 is being
explored (43), although this may be hampered by the ubiq-
uitous expression of this G-protein–coupled receptor, which
is thought to be critical in development, inflammation,
immunity, and angiogenesis (44), as well as important in
protecting musculoskeletal tissues from the destructive
effects of inflammation and in promoting regeneration (45).
Since our ex vivo findings were made using only the
recombinant catalytic domain of matriptase, and since
inclusion ofmatriptase inhibitors abolished cartilage degra-
dation (results not shown), we concluded that our observa-
tions are dependent on matriptase activity. Indeed,
inhibition of matriptase activity as a potential therapeutic
approach to treating OA was demonstrated using 2 differ-
ent methods of inhibiting this transmembrane serine pro-
teinase. We previously reported the potent inhibitory
capacity of antibody A11 for matriptase (22,46), and in the
present study we demonstrated its ability to reduce carti-
lage damage when administered in vivo to DMM-operated
mice at a similar dosage as that used for a neutralizing
PAR-2 antibody study (13). Furthermore, both systemic
administration and intraarticular delivery of a small
molecule inhibitor of matriptase, compound 59 (24,25), sig-
nificantly reduced cartilage damage in a dose-dependent
manner. Immunohistochemistry revealed this was likely due
to reducedmetalloproteinase activity (consistent with the use
ofGM6001 inmatriptase-stimulated humanOAcartilage) as
evidenced by reduced ADAMTS- and MMP-mediated
aggrecan cleavage as well as reduced collagenase-mediated
cleavage of type II collagen.
The relatively low level of staining for the
aggrecanase-mediated NVTEGE epitope is likely due to
the concomitant MMP activity which effectively facilitates
diffusion of the short ADAMTS/MMP-generated aggrecan
fragment (Phe342-Glu373; human sequence numbering)
(47) while leaving a residual G1 aggrecan monomer with
the MMP-generated VDIPEN C-terminus. Although we
did not confirm the presence of the Phe342-Glu373 peptide
from matriptase-treated human OA cartilage, if it is pres-
ent, this bioactive peptide could further contribute to carti-
lage breakdown via Toll-like receptor 2 (48). Together,
these findings reveal that modulation of matriptase activity
can regulate the in vivo proteolytic burden ofOA cartilage.
We and others have previously demonstrated the
ability of matriptase to activate several proMMPs (10) and
have proposed that proMMP activation represents a key
rate-limiting step in cartilage destruction in disease
(5–7,21). The mechanisms by which matriptase is regulated
in cartilage are unknown, although we have detected
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matriptase in murine cartilage following OA induction
(10), which suggests that biomechanical mechanisms are
important in this process. An intriguing feature of
matriptase is that it automatically activates by a process that
remains somewhat unclear (10,49). This unusual property
for a serine proteinase ideally places it as an initiator of pro-
teolytic cascades, and our findings further support the con-
cept that matriptase is a key proMMP activator in OA (10).
Osteophyte formation is a characteristic of OA, but
a correlation with cartilage damage is not always apparent.
For example, osteophytes in MMP-13–deficient mice were
no different in size at 8 weeks post-DMM (30), and in our
previous study, we found no osteophyte differences in
DMM-treated mice with exacerbated cartilage damage
(29). Furthermore, results from our recent study showed
reduced osteophyte size in PAR-2–deficient mice following
DMM, which are protected against cartilage damage (50),
although an increase in osteophyte bone density was evi-
dent. With increasing doses of matriptase inhibitor we saw
a trend toward reduced osteophyte size, suggesting perhaps
that sufficient delivery of a potent matriptase inhibitor
would also reduce osteophyte formation. Further research
will be required to fully assess this latter possibility.
The cumulative impact of cartilage damage, which
is perpetuated by multiple direct and indirect mechanisms
over many years, is a significant contributing factor to OA
progression and offers the potential for therapeutic inter-
vention. Since aggrecanolysis appears to be a fundamental
prerequisite for the essentially irreversible collagen break-
down (16,19), there has been intense debate surrounding
the most appropriate target for future therapy (51). In the
present study, our findings demonstrate that matriptase
indirectly promotes potent destruction of aggrecan via the
action of bothMMPs and aggrecanases, the levels of which
may remain elevated in OA cartilage due to LRP-1 release
by matriptase. Finally, since effective inhibition of
matriptase activity markedly reduces metalloproteinase
activities and cartilage damage in vivo, we conclude that
this serine proteinase is attractive therapeutically, and we
suggest that targeting matriptase activity could serve as a
potent, effective DMOAD.
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